Loading…
Loading the latest PSX data…
Loading the latest PSX data…
BF Biosciences Limited (BFBIO), GlaxoSmithKline Pakistan Limited (GLAXO): performance, valuation, growth, risk and danioPSX score, side by side.
Add a stock
Growth of Rs 100 from 2025-11-11
Daily closes from PSX end-of-day files, adjusted for bonus shares, right issues and splits (not for cash dividends). KSE-100: official closes where available, otherwise rebuilt from its constituents.
| Measure | BFBIOPharmaceuticals | GLAXOPharmaceuticals |
|---|---|---|
| danioPSX score | 44 | 89 |
| Price and size | ||
| Price | Rs 136.13 | Rs 339.59 |
| Today | +0.64% | +0.96% |
| Market cap | Rs 12.0bn | Rs 108.1bn |
| Traded per day | Rs 16m | Rs 49m |
| Valuation and dividends | ||
| P/E | 18.3 | 9.9 |
| Dividend yield | – | 6.1% |
| EPS (last year) | Rs 7.16 | Rs 31.48 |
| Business | ||
| EPS growth | +29.7% | +53.4% |
| Sales growth | +62.1% | +7.7% |
| Net margin | 6.7% | 15.2% |
| Returns | ||
| 1 month | +4.8% | +8.9% |
| 3 months | +0.1% | −1.6% |
| 1 year | −10.1% | −13.9% |
| vs KSE-100, 1 year | -23.2 pts | -27.0 pts |
| Trend and risk | ||
| 52-week position | 31% | 28% |
| RSI 14 | 66 | 65 |
| RS rank | 47 | 42 |
| Volatility | 36% | 34% |
| Beta | 0.96 | 1.05 |
| danioPSX score | ||
| Value | 27 | 69 |
| Quality | 67 | 81 |
| Dividend | 0 | 64 |
| Momentum | 46 | 40 |
| Safety | 74 | 80 |
| Shariah-compliant | Yes | Yes |
Bold marks the best value in each row where higher (or, for P/E and volatility, lower) is clearly better.
A comparison of published numbers, not a recommendation. Share this page: the address holds the stocks. Find more stocks with the screener